PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]PF-06882961, 50 mgDrug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04495140
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇳🇱PRA Health Sciences Utrecht, Utrecht, Netherlands
Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment
Phase 1
Completed
- Conditions
- Renal Insufficiency
- Interventions
- Drug: Aztreonam-Avibactam
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT04486625
- Locations
- 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG
Phase 1
Completed
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Drug: 4 mg Fesoterodine ER tablet from ZwickauDrug: 4 mg fesoterodine ER tablet from FreiburgDrug: 8 mg fesoterodine ER tablet from ZwickauDrug: 8 mg fesoterodine ER tablet from Freiburg
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT04478357
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT04460898
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT04460911
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1
Active, not recruiting
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT04458259
- Locations
- 🇺🇸
Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Community Health Network Investigational Drug Services, Indianapolis, Indiana, United States
🇺🇸Rocky Mountain Lions Eye Institute (RMLEI), Aurora, Colorado, United States
Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: VupanorsenDrug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04459767
- Locations
- 🇯🇵
P-one Clinic, Hachioji-shi, Tokyo, Japan
InO - A Retrospective Study of UK Patients With Leukaemia
Completed
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT04456959
- Locations
- 🇬🇧
University College London Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧The Royal Marsden NHS Foundation Trust of Fulham Road, London, United Kingdom
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer
Phase 1
Completed
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Drug: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)Drug: Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)Drug: Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)Drug: Fesoterodine BIC SR4 fed (Treatment E in Part B)Drug: Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT04452838
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
Completed
- Conditions
- Major Depression
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath